Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (7314)	3/12/2002 3:42:01 PM
From: BW	Respond to of 48461

ASTM just got real cheap. Boyd

To: Bucky Katt who wrote (7314)	3/13/2002 9:06:59 AM
From: BW	Read Replies (2) \| Respond to of 48461

CRXA - dcb play today? whacked down 50% on FDA news. already up about 15% premkt. Corixa Receives Complete Review Letter On BEXXAR SEATTLE--(BW HealthWire)--March 13, 2002--Corixa Corporation (Nasdaq:CRXA - news), a developer of immunotherapeutics, today announced the receipt of a complete review letter from the U.S. Food and Drug Administration (FDA) regarding the Biological License Application (BLA) for BEXXAR® (tositumomab, iodine I-131 tositumomab), an investigational radioimmunotherapy for the treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma. Bexxar is being co-developed by Corixa and GlaxoSmithKline in the United States. In the Complete Review letter received in the evening of March 12, 2002, the FDA stated that in its opinion, Corixa's September 10, 2001 response to the Agency's March 16, 2001 Complete Review letter did not provide sufficient evidence of the safety and net clinical benefit of BEXXAR and further stated that additional clinical studies will be required to provide such evidence. Regarding Corixa's prior request for Accelerated Approval, the letter stated that the data reviewed by the Agency do not provide sufficient evidence that BEXXAR addresses an unmet medical need. Additionally, the letter stated that within 10 days from its receipt, Corixa must either amend its application, notify the Agency of its intent to file an amendment, withdraw the application or request an opportunity for a hearing on whether there are grounds for denying approval of the application. Corixa will formally request a meeting with representatives of the Agency for further discussion of a regulatory path for BEXXAR. It is expected that this meeting will occur within the next 45 days. ``We are extremely disappointed with the FDA's decision and intend to promptly pursue resolution with our partner, GlaxoSmithKline and the Agency,'' stated Steven Gillis, Ph.D., Corixa chairman and chief executive officer. ``We are formally requesting a meeting with the FDA and hope to reach mutual agreement on the specific steps still necessary for approval. We will provide additional guidance as to the regulatory pathway for BEXXAR after further discussions with GlaxoSmithKline and the FDA.'' About Corixa Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a stand-alone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar®, a monoclonal antibody conjugated to a radioisotope.